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Letter to the Editor
In Iraq, the diagnosis of acute leukemia is essentially based on 
clinical presentation and the basic hematological investigations 
including complete blood count and blood smear morphology, 
after which a bone marrow aspirate and sometimes a trephine 
biopsy will follow. These measures usually permit the diagnosis of 
most varieties of acute leukemias with a very acceptable level of 
reliability. However, there is still a small percentage of cases that 
can never be diagnosed based only on morphological features.
Moreover, here in Iraq, there is absence of genetic analysis, 
apart from limited molecular by genetics polymerase chain reac-
tion (PCR) only for CML BCR-ABL1 oncogene. There is also an 
absence of flow cytometry and immunophenotyping panels, apart 
from individual, never in complete panels and inconsistently avail-
able/few CD markers study using immunohistochemistry. 
Therefore, a chemotherapeutic trial for those who can not 
afford to seek a more precise diagnosis with genetic study and 
lineage specification outside this country is a realistic option, as 
the response to treatment could be a very useful confirmation of 
the provisional diagnosis. The two examples already faced are 
AML-M3v diagnosed provisionally only by morphology but with a 
dramatic response to all-trans-retinoic acid (ATRA) trial, confirm-
ing the diagnosis [1] and a few cases of morphologically undif-
ferentiated acute leukemia in which the induction therapy for ALL 
is tried first. If the patient responds, then a diagnosis of ALL can 
be deduced; if not, the regimen should be shifted to chemo-
therapy of AML.
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